The preclinical LNPs are similar to the ones used for human vaccines, which could also explain the observed side effects in humans using this platform.
To improve the stability of mRNA-LNP vaccines, optimization of the mRNA nucleotide composition should be prioritized. Secondly, a better understanding of the milieu the mRNA is exposed to in the core of LNPs may help to rationalize adjustments to the LNP structure to preserve mRNA integrity. Moreover, drying techniques, such as lyophilization, are promising options still to be explored.
NANOMATERIAL DELIVERY SYSTEMS FOR MRNA VACCINES